Patents by Inventor Carl F. Nathan

Carl F. Nathan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132480
    Abstract: Disclosed are compounds for inhibiting lipoamide dehydrogenase (Lpd), and methods of treating tuberculosis.
    Type: Application
    Filed: January 7, 2022
    Publication date: April 25, 2024
    Inventors: John Ginn, Shan SUN, Mayako Michino, Nigel Liverton, Rui Liang, Peter T. Meinke, David Huggins, Ruslana Bryk, Carl F. Nathan
  • Patent number: 8338465
    Abstract: Disclosed are methods for the prevention or treatment of tuberculosis in a subject infected with Mycobacterium tuberculosis by administering rhodanine derivatives of formula (I), as well as some novel such compounds. Other embodiments are also disclosed.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: December 25, 2012
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Jasbir Singh, Carl F. Nathan, Ruslana Bryk, Raghu Samy, Krzysztof Pupek, Mark Gurney
  • Publication number: 20100210577
    Abstract: Disclosed are methods for the prevention or treatment of tuberculosis in a subject infected with Mycobacterium tuberculosis by administering rhodanine derivatives of formula (I), as well as some novel such compounds. Other embodiments are also disclosed.
    Type: Application
    Filed: June 8, 2007
    Publication date: August 19, 2010
    Inventors: Jasbir Singh, Carl F. Nathan, Ruslana Bryk, Raghu Samy, Krzysztof Pupek, Mark Gurney
  • Patent number: 7282491
    Abstract: The present invention relates to methods of treating Mycobacterium pathogen infection in a subject that involve: inhibiting proteasomal activity in a pathogen under conditions effective to make the pathogen susceptible to antibacterial host defenses; inhibiting enzyme activity in a pathogen under conditions effective to make the pathogen susceptible to antibacterial host defenses, where the enzyme is a DNA repair enzyme or a flavin-like co-factor synthesis enzyme, or inhibiting proteasomal and enzyme activity under conditions to make the pathogen susceptible to antibacterial host defenses. The present invention also relates to methods for screening compounds that inhibit proteasomal and protease activity, DNA repair enzyme activity, or flavin-like co-factor synthesis enzyme activity, where the inhibitory compounds have an ability to sensitize bacteria to the antibacterial effects of oxidative/nitrosative stress.
    Type: Grant
    Filed: December 8, 2003
    Date of Patent: October 16, 2007
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Katerina Heran Darwin, Carl F. Nathan
  • Publication number: 20040213776
    Abstract: The present invention relates to methods of treating pathogen infection in a subject that involve: inhibiting proteasomal activity in a pathogen under conditions effective to make the pathogen susceptible to antibacterial host defenses; inhibiting enzyme activity in a pathogen under conditions effective to make the pathogen susceptible to antibacterial host defenses, where the enzyme is a DNA repair enzyme or a flavin-like co-factor synthesis enzyme, or inhibiting proteasomal and enzyme activity under conditions to make the pathogen susceptible to antibacterial host defenses. The present invention also relates to methods for screening compounds that inhibit proteasomal and protease activity, DNA repair enzyme activity, or flavin-like co-factor synthesis enzyme activity, where the inhibitory compounds have an ability to sensitize bacteria to the antibacterial effects of oxidative/nitrosative stress.
    Type: Application
    Filed: December 8, 2003
    Publication date: October 28, 2004
    Inventors: Katerina Heran Darwin, Carl F. Nathan
  • Publication number: 20030190325
    Abstract: The present invention relates to methods of preventing and treating tuberculosis in a subject infected with Mycobacterium tuberculosis. The method involves inhibiting AhpD in the subject under conditions effective to make the pathogen susceptible to antimicrobial reactive nitrogen intermediates or reactive oxygen intermediates. The present invention also relates to methods of preventing and treating tuberculosis in a subject infected with Mycobacterium tuberculosis involving inhibiting dihydrolipoamide dehydrogenase or dihydrolipoamide succinyltransferase in Mycobacterium tuberculosis in the subject under conditions effective to make the pathogen susceptible to antimicrobial reactive nitrogen intermediates or reactive oxygen intermediates. Also disclosed are methods for identifying candidate compounds suitable for treatment or prevention of tuberculosis.
    Type: Application
    Filed: January 15, 2003
    Publication date: October 9, 2003
    Inventors: Carl F. Nathan, Christopher D. Lima, Ruslana Bryk
  • Patent number: 6177086
    Abstract: The present invention relates to a DNA molecule conferring on Mycobacterium tuberculosis resistance to antimicrobial reactive oxygen intermediates and reactive nitrogen intermediates. The protein encoded by this DNA molecule is useful in vaccines to prevent invention by Mycobacterium tuberculosis, while the antibodies raised against this protein can be employed in passively immunizing those already infected by the organism. Both these proteins and antibodies may be utilized in diagnostic assays to detect Mycobacterium tuberculosis in tissue or bodily fluids. The protein or polypeptide is also useful as a therapeutic in treating conditions mediated by the production of reactive oxygen intermediates and nitrogen intermediates.
    Type: Grant
    Filed: April 28, 1998
    Date of Patent: January 23, 2001
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Lee W. Riley, Carl F. Nathan, Sabine Ehrt
  • Patent number: 5766909
    Abstract: Complementary DNAs (cDNAs) encoding inducible nitric oxide synthase are isolated and purified from a cDNA library prepared from macrophage-like cells activated with interferon gamma and bacterial lipopolysaccharide. The full length cDNAs of at least two isoforms of the enzyme are identified and sequenced.
    Type: Grant
    Filed: November 5, 1993
    Date of Patent: June 16, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Qiao-Wen Xie, Carl F. Nathan, Richard A. Mumford, Jimmy Ramos Calaycay
  • Patent number: 5654167
    Abstract: The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
    Type: Grant
    Filed: March 8, 1994
    Date of Patent: August 5, 1997
    Assignees: Cornell Research Foundation, Inc., Rockefeller University
    Inventors: Joelle E. Gabay, Carl F. Nathan
  • Patent number: 5132407
    Abstract: Inducible nitric oxide (NO) synthase flavoprotein purified to an activity more than 400-fold from activated mouse macrophage cell line is water soluble, has a denatured molecular mass as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis under reducing conditions ranging from 125 to 135 kDa, has a molecular mass in catalytically active form of about 250 kDa, does not require added calcium ions or calmodulin for activity, and on heat denaturation releases flavin adenine dinucleotide in an amount of 1.1.+-.0.1 mol per mol of 130 kDa polypeptide subunit of the purified flavoprotein and flavin mononucleotide in an amount of at least 0.55.+-.0.04 mol per mol of 130 kDa polypeptide subunit of the purified flavoprotein.
    Type: Grant
    Filed: September 26, 1991
    Date of Patent: July 21, 1992
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Dennis J. Stuehr, Carl F. Nathan
  • Patent number: 5126257
    Abstract: The present invention provides a composition of matter useful as an antimicrobial agent. This composition of matter comprises an extract derived from human polymorphonuclear leukocytes, said extract including a polypeptide having an apparent molecular weight of about 13,000 daltons, a polypeptide having an apparent molecular weight of about 29,000 daltons and a polypeptide having an apparent molecular weight of about 54,000 daltons. The extract also has oxygen-independent, antimicrobial activity for bacteria and fungi at a pH from about 5.0 to about 8.0 and at calcium ion concentrations up to about 10 mM, bactericidal activity at sodium chloride concentrations up to about 0.3M, and fungicidal activity at sodium chloride concentrations up to about 0.15M. Methods for preparing this composition of matter are also provided. Further provided are purified polypeptides useful as antimicrobial agents, and methods for producing these polypeptides.
    Type: Grant
    Filed: October 6, 1987
    Date of Patent: June 30, 1992
    Assignees: Cornell Research Foundation, Rockefeller University
    Inventors: Joelle E. Gabay, Carl F. Nathan
  • Patent number: 5087569
    Abstract: The present invention provides a composition of matter useful as an antimicrobial agent. This composition of matter comprises at least two polypeptides selected from the group consisting of human polymorphonuclear leukocyte, polypeptides having on apparent molecular weights of about 3,500 daltons, about 13,000 daltons, about 18,000 daltons, about 29,000 daltons, and about 54,000 daltons. The composition of matter has respiratory burst-independent, antimicrobial activity for bacteria and fungi at a pH from about 5.0 to about 8.0 and at calcium ion concentrations up to about 10 mM, bactericidal activity at sodium chloride concentrations up to about 0.3M, and fungicidal activity at sodium chloride concentrations up to about 0.15M. Methods for preparing this composition of matter are also provided. Further provided are purified polypeptides useful as antimicrobial agents, and methods for producing these polypeptides.
    Type: Grant
    Filed: November 25, 1987
    Date of Patent: February 11, 1992
    Assignee: Cornell Research Foundation, Inc. and The Rockefeller University
    Inventors: Joelle E. Gabay, Carl F. Nathan